Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
alnuctamab (CC-93269) / BMS
Alnuctamab, a BCMA x CD3 T-Cell Engager, in Patients with Relapsed ...
(Alnuctamab) - 药物靶点：BCMA x CD3_在研适应症：多发性骨髓瘤，复发性多发性骨髓瘤_专利_临床_研发
Comprehensive Review of Bispecific Antibody Constructs In Multiple ...
BCMA/CD3 Bispecific Antibodies for Multiple Myeloma (MM) | Biopharma PEG
Alnuctamab- Bispecific Antibody | Therapies on the Horizon #myeloma ...
Buy Research Grade Alnuctamab biosimilar
Study on Alnuctamab and Drug Combination for Patients with Relapsed or ...
Current use of bispecific antibodies to treat multiple myeloma - PMC
Alnuctamab – Application in Therapy and Current Clinical Research
Frontiers | Bispecific antibody targets and therapies in multiple myeloma
P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ...
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell ...
Alnuctamab (EM901) | T细胞接合器 | MCE
ALNUCTAMAB • Clasificación Arancelaria
Current State of the Art and Prospects of T Cell-Redirecting Bispecific ...
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen ...
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation ...
2023AACR丨再生元公布BCMA/CD3双抗数据及计划 再生元 目前有两款BCMA/CD3双抗，REGN5459和REGN5458。今年的 ...
Alnuctamab Myeloma Trials
Alnuctamab: improved route of administration and optimized dose level ...
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma ...
(PDF) P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T ...
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma ...
Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T ...
Bristol shows its alnuctamab hand | ApexOnco - Clinical Trials news and ...
Mechanisms of resistance against T-cell engaging bispecific antibodies ...
Relapsed/Refractory Multiple Myeloma Highlights from ASH 2022 - The ...
(PDF) P799: SYNERGISTIC ANTITUMOR ACTIVITY OF THE BCMA 2 + 1 T CELL ...
Subcutaneous alnuctamab in patients with R/R multiple myeloma: the ...
Frontiers | Bispecific antibodies for the treatment of relapsed ...
Slide 50
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance ...
P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS ...
Results from Phase I study of alnuctamab administered intravenously ...
Synergistic activity of alnuctamab and CELMoDs in multiple myeloma ...
Slide 51
Mechanism of action of Aducanumab. | Download Scientific Diagram
阿尔茨海默病患者的曙光——Aducanumab抗体的发现 - 脑医汇
ASH 2022：BMS的CD3/BCMA双抗Alnuctamab治疗RRMM初步数据公布-MedSci.cn
P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ...
Teclistamab for multiple myeloma | CMAR
The value of subcutaneous alnuctamab for the treatment of R/R multiple ...
Frontiers | Bispecific antibodies in multiple myeloma treatment: A ...
本周FDA新药获批，国内创新药获批、NDA和IND；全球III期临床汇总_腾讯新闻
(PDF) P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME ...
Antitumor activity of alnuctamab in combination with CELMoDs in ...
Frontiers | Next Generation CD40 Agonistic Antibodies for Cancer ...
Atezolizumab: Unveiling the Role of Anti-PD-L1 in Cancer Research ...
Evolving Therapeutics in Multiple Myeloma – Empower MM
Benefits of alnuctamab in the treatment of R/R multiple myeloma - YouTube
(PDF) Mechanisms of antigen escape from BCMA- or GPRC5D-targeted ...
PPT - BCMACD3 Bispecific Antibodies for Multiple Myeloma (MM ...
靶向B细胞淋巴瘤的新兴抗体疗法-鸡/绵羊/猪单克隆抗体定制-德泰生物
The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies ...
Full article: Targeting B Cell Maturation Antigen in Patients with ...
Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for ...
Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1
Alnuctamab for Refractory SLE (LATTE Study)
T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions
American Journal of Hematology | Blood Research Journal | Wiley Online ...
双特异性T细胞衔接器（TCE）-CD3双抗-TCE作用机制/技术平台-德泰生物
Phase I first-in-human study of alnuctamab in patients with R/R ...
Structural features and binding affinity of BK1 (BCMA×CD16A) bispecific ...
Monoallelic TNFRSF17 deletion coupled with deletion of Pro34 in the ...
Frontiers | Efficacy and safety of bispecific antibodies therapy for ...
Neil Webb | CONCEPTUAL ILLUSTRATION PROCESS
All about blinatumomab: the bispecific T cell engager immunotherapy for ...
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA ...
Aducanumab获批之后，阿尔茨海默病新药开发风起云涌 6月7日，FDA基于生物标志物替代终点加速批准渤健/卫材公司Aβ（β淀粉样蛋白 ...
Frontiers | B cell depletion therapies in autoimmune diseases ...
JCI - B cell depletion: a novel therapy for autoimmune diabetes?
Bispecific Antibodies: Expanding the Frontiers of Targeted Immunotherapy
Can Antibodies Poke Holes In Cells at Toby Wise blog
BCMACD3 Bispecific Antibodies for Multiple Myeloma (MM).pdf
Dr. Harvey: Infections and ICANS are both listed here. Again, similarly ...
bispecific T-cell engager Archives | VJHemOnc
Antibody Cell Depletion at Walter Abbott blog
Sandy Wong, MD, Discusses Phase I Trial of Alnuctamab in Relapsed ...
PPT - Blinatumomab: A Bispecific CD19-directed CD3 T-cell Engager ...
Ichnos Glenmark于《Nature Cancer》发布首款BCMA/CD38/CD3三特异性抗体ISB 2001的临床前研究数据 - 知乎
Full article: Bispecific antibodies: design, therapy, perspectives
Diagnosis and Therapeutic Advances in Multiple Myeoma | BLCTT
Full article: A pivotal decade for bispecific antibodies?
Current landscape of CD3 bispecific antibodies in hematologic ...
Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager ...
Legend CEO spells out path to $5B in sales for multiple myeloma CAR-T ...
Blinatumomab for the treatment of acute lymphoblastic leukemia ...
Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed ...
00186-8/asset/80fa396a-9046-4821-9fd0-46d6f23088e2/main.assets/gr1_lrg.jpg)
00186-8/asset/3a18e16c-69c8-42fc-a578-8c64c5663600/main.assets/gr2.jpg)
